Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Slow but positive change? The evolution of section 3d
Asia
New definitions of efficacy are helping to clarify pharmaceutical patent challenges under the notorious Section 3d of the Indian Patents Act, says Rahul Vartak.   1 April 2013
Who's first? New rules on filing patents
Americas
On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.   1 April 2013
India: a threat to an industry or just misunderstood?
Asia
To read much of the reaction to recent pharmaceutical rulings in India, you might think that the country is waging a war against Western innovation. But while there is certainly cause for concern, that’s not the whole story, as LSIPR finds out.   1 April 2013
Americas
Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate.   1 April 2013
Big Pharma
Gordon Wright reviews the key SPC cases as Europe’s SPC Regulation for medicinal products approaches its 21st birthday.   28 March 2013
Big Pharma
When most people hear the word counterfeiting, they think of fashion, but as Bruce Longbottom of Eli Lilly and Company explains, drugs are a key target too.   28 March 2013
Big Pharma
The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.   28 March 2013
Americas
For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities.   28 March 2013
Sectors
Oxitec’s pioneering insect sterilisation technique could eradicate dengue fever and malaria and cut crop damage worldwide. LSIPR spoke to CEO Hadyn Parry about the company’s development and its approach to protecting its inventions.   28 February 2013
Asia-Pacific
The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues.   1 February 2013